INSIDE-SECURE
Regulatory News:
Inside Secure (Paris:INSD), at the heart of security solutions for mobile and connected devices, today announced general availability of Inside Secure Advertising Protection solutions at IBC 2018 , the world’s most influential media, entertainment and technology show, Sept 14-18 in Amsterdam.
Unlike other ad protection products, Inside Secure’s solutions ensure the correct advertising content is viewed by the intended audience while also maximizing revenues for global over-the-top (OTT) advertising distributors and publishers. With the industry facing ever-increasing challenges from ad blockers and hackers who block or alter ad tracking information, Inside Secure’s technology uniquely prevents the same ad from being reported or counted more than once and ensures an ad is not replaced or coming from illegitimate sources. Inside Secure’s Advertising Protection solutions can notify viewers, when required, that ad blocker apps must be removed before viewing content.
This solution offers three modules:
- Advertising Protection Client– Protects ad tracking information against ad blockers as well as hacker replay, replacement and spoofing attacks
- Advertising Protection Server– Runs on a server and secures the communication between a client device displaying ads and the ad server
- Advertising Protection Service – A service operated by Inside Secure that tracks fraudulent activity on end user devices and displays its impacts (ratio of legal calls versus illegal calls)
“With billions in revenues lost each year, ad blocking and ad fraud are severe, fast-growing problems that Inside Secure is uniquely positioned to cost-effectively and efficiently address for content publishers,” said Simon Blake Wilson, COO at Inside Secure. “By protecting the advertising delivery channel itself, we offer a future-proof suite of tools to maximize revenues while ensuring peace of mind through continual updates of ad blocking and fraud detection heuristics in app algorithms. Our long-time cybersecurity expertise perfectly pairs with the needs of today’s content publishers.”
Live demos of Inside Secure’s Advertising Protection solutions are available at the company’s IBC 2018 A40 booth in Hall 14. For more information, visit https://www.insidesecure.com/Company/More/Events/IBC-2018 .
About Inside Secure
Inside Secure (Euronext Paris – INSD) is
at the heart of security solutions for mobile and connected devices,
providing software, silicon IP, services and the know-how needed to
protect customers’ transactions, identity, content, applications and
communications. With its deep security expertise, the company delivers
products that span the entire range of security requirement levels to
serve the demanding markets of network security, IoT, System-on-Chip
security, video content and entertainment, mobile payment and banking,
enterprise and telecom. Inside Secure’s technology protects solutions
for a broad range of customers including service providers, operators,
content distributors, security system integrators, device makers and
semiconductor manufacturers. Visit www.insidesecure.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005418/en/
Contact:
PR Contact: Brigitte Foll, Marketing Communications Director Inside Secure communication@insidesecure.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom